The Semax peptide is a synthetic analogue of the adrenocorticotropic hormone (ACTH 4–7), modified to enhance stability and biological activity. Originally developed in Russia, it has been extensively studied for its neuroprotective and nootropic properties, particularly in the context of cognitive function, stroke recovery, and neural resilience. Its scientific significance lies in its ability to influence multiple brain pathways without triggering the hormonal effects typically associated with full-length ACTH.